Balancing Long-Term Efficacy and Immunological Safety: Serious Infection Risk during Extended Ocrelizumab Therapy in Multiple Sclerosis

Abstract

Highly efficient treatments for Multiple sclerosis (MS) have changed the treatment strategy in a way that relapse rates are minimized and clinical disease activity is prevented. The use of the Ocrelizumab over a longer period, however, raises the issue of immunological safety and infection risks. This review looked at all the information about infections that people got when they used Ocrelizumab for a long time. Additionally, we reviewed the effectiveness of ocrelizumab therapy within the term and the types of infections suffered by individuals. In addition, we considered a disease known as hypogammaglobulinemia and the ways it is presently screened. In this paper we used PubMed and Google Scholar as our databases to identify relevant data between (2016-2026). Twenty articles concerning the topic of adult sclerosis have been identified. These adults have been diagnosed with sclerosis based on the McDonald criteria. Ocrelizumab is a drug that is an anti-CD20 monoclonal antibody. It works well for people with relapsing and progressive MS. It reduces the number of relapses and stops the disease from getting worse plus, it decreases the number of lesions on the MRI. However, within long-term taking of this medication, depletion of B cells happened, and it could lead to the gradual suppression of humoral immunity due to IgM and then IgG depletion. Decreased IgG is associated with the high risk of infections; however, the suggested guidelines for monitoring (IgG < 4 g/L and change in therapy if IgG drops to 3-3.5 g/L) lack evidence. Common infections include respiratory and soft tissue infections, UTIs, and herpes zoster. Rare opportunistic infections include hepatitis B infection reactivation and progressive multifocal leukoencephalopathy, which is more often caused by prior disease-modifying treatments. Monitoring should consist of baseline evaluation of tuberculosis, hepatitis B, and HIV infection; regular complete blood counts and immunoglobulin levels; immunization prior to therapy; and the possibility of extending dosing intervals, immunoglobulin replacement, or switching therapy for recurrent infections or severe reduction in IgG levels. In general, prolonged ocrelizumab is an effective treatment of MS, although the risk of infection is significant, cumulative, and requires personalized immune monitoring.